Novo Nordisk Raises 2023 Sales Outlook on Strong Demand for Wegovy and Ozempic

Novo Nordisk has raised its full-year sales and operating profit outlook due to high demand for its weight loss drug Wegovy and diabetes treatment Ozempic.